Qube Research & Technologies (QRT)’s Whitehawk Therapeutics WHWK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$167K Sell
48,307
-24,041
-33% -$75.3K ﹤0.01% 2991
2025
Q4
$175K Buy
+72,348
New +$166K ﹤0.01% 3081
2024
Q3
Sell
-12,071
Closed -$17.6K 4290
2024
Q2
$17.6K Buy
+12,071
New +$22.4K ﹤0.01% 2897
2023
Q4
Sell
-106
Closed -$513 4832
2023
Q3
$513 Buy
+106
New +$616 ﹤0.01% 3677
2022
Q2
Sell
-17,333
Closed -$294K 3231
2022
Q1
$294K Buy
+17,333
New +$332K ﹤0.01% 1799
2021
Q2
Sell
-801
Closed -$16K 2889
2021
Q1
$16K Sell
801
-3,735
-82% -$86K ﹤0.01% 1826
2020
Q4
$67K Sell
4,536
-12,452
-73% -$266K ﹤0.01% 1679
2020
Q3
$382K Buy
16,988
+14,759
+662% +$311K 0.01% 1139
2020
Q2
$42K Buy
+2,229
New +$29.2K ﹤0.01% 1616

Other funds holding WHWK

Qube Research & Technologies (QRT)'s WHWK Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Whitehawk Therapeutics (WHWK) stake by 33% in Q1 2026, selling an estimated $75.3K and leaving 48,307 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #2991.

Qube Research & Technologies (QRT) first reported a position in WHWK in Q2 2020 and has held it in 9 quarters since. The position peaked at $382K in Q3 2020. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Qube Research & Technologies (QRT) held 48,307 shares of Whitehawk Therapeutics worth $167K as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 24,041 Whitehawk Therapeutics shares in Q1 2026, an estimated $75.3K.
  • Whitehawk Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2991 holding.
  • Qube Research & Technologies (QRT) first reported a position in Whitehawk Therapeutics in Q2 2020 and has held it in 9 quarters since.
  • Qube Research & Technologies (QRT)'s Whitehawk Therapeutics position peaked at $382K in Q3 2020.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.